Predicating the sensibility of patients with multiple myeloma to glucocorticoid by cochaperone P23.
- Author:
Jun XUE
1
;
Xiao-Jing XIE
;
Peng CAO
Author Information
1. Department of Hematology, Nanjing Medical University, Nanjing, Jiangsu Province, China. xuejun64@sina.com
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Female;
Glucocorticoids;
pharmacology;
therapeutic use;
HSP90 Heat-Shock Proteins;
metabolism;
Humans;
Male;
Middle Aged;
Molecular Chaperones;
metabolism;
Multiple Myeloma;
diagnosis;
drug therapy;
metabolism;
Phosphoproteins;
metabolism;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2012;20(1):103-106
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the sensitive index for predicting the sensitivity of patients with multiple myeloma (MM) to glucocorticoid (GC). MM1.S, MM1.R cell lines and 10 MM patients sensitive or non-sensitive to GC were enrolled in this study. The expression of heat shock protein 90 (HSP90) and P23 in peripheral blood mononuclear cells (PBMNC) of MM patients was detected by Western blot, and its relation with GC resistance was explored. The results showed that there were no differences in HSP90, GR and IκB-α expressions among MM1.S, MM1.R, PBMNC of normal persons and MM patients, while there was apparent difference in P23; along with increasing of dexamethasone dose, the survival rate of MM1.S decreased, but that of MM1.R did not change so obviously. Among 7 cases with P23 low expression, combination treatment scheme with GC was effective in 6 cases (86%), uneffective in 1 cases (14%); while among 3 cases with P23 high expression, 1 cases (33%) showed effective to combination treatment with GC, 2 cases (67%) showed uneffective (P < 0.05). It is concluded that the P23 expression may predict the sensitivity of MM patients to GC and may be used as index for guiding clinical treatment.
